CLINUVEL Newsletter – December 2017

07 December 2017

The CLINUVEL team is looking with much optimism and energy to the start of 2018. I believe the year ahead is one where the Company will make great strides on various fronts: research, product development, distribution, and restructuring of the Group of companies. We all eagerly await the day our teams can supply SCENESSE® (afamelanotide 16mg) to US erythropoietic protoporphyria (EPP) patients who endlessly request updates on progress. That very day will be the epitome of CLINUVEL’s lengthy crusade, and a most fulfilling professional moment.

Download PDF for more

We use cookies to give you the best experience.